Evidence-Based Project – Paper on Diabetes
Hi, Please write Small essay with more bullet points. Prepare a short essay (550 words). Please write an essay based on the Research Article which I attached. Also you can check http://diabetes(dot)niddk(dot)nih(dot)gov/ website for more reference. Details here. Assignment : Benchmark Assignment: Evidence-Based Practice Project—Intervention Presentation on Diabetes Details: Small essay with bullet points Essay Based on the summary of research findings identified from the Evidence-Based Project—Paper on Diabetes that describes a new diagnostic tool or intervention for the treatment of diabetes in adults or children, complete the following components of this assignment: Small essay with more bullet points. Prepare a short essay (550 words) that includes the following: Please add reference too 1. A brief summary of the research conducted in the Evidence-Based Project – Paper on Diabetes. 2. A descriptive and reflective discussion of how the new tool or intervention may be integrated into practice that is supported by sound research. Note: Prepare essay with more bullet points.
Assignment : Benchmark Assignment: Evidence-Based Practice Project—Intervention Presentation on Diabetes
Details: Small essay with bullet points Essay
Based on the summary of research findings identified from the Evidence-Based Project—Paper on Diabetes that describes a new diagnostic tool or intervention for the treatment of diabetes in adults or children, complete the following components of this assignment:
Small essay with more bullet points. Prepare a short essay (550 words)
that includes the following: Please add reference too
- A brief summary of the research conducted in the Evidence-Based Project – Paper on Diabetes.
- A descriptive and reflective discussion of how the new tool or intervention may be integrated into practice that is supported by sound research.
Note: Prepare essay with more bullet points.
Name:
Institution:
Date:
Summary of the Research
* A multicenter, double-blind placebo-controlled clinical trial was used.
* Involved 408 randomized patients.
* Randomized patients with HbA1c of 7.0%, 140mg/dl Fasting Plasma Glucose, and 1 ng/ml C-peptide
* The patients received a placebo or 7.5, 15, 30, or 45 mg of Pioglitazone (o.d) for 26 weeks.
* Significant mean decrease for patients receiving 15, 30, or 45 mg Pioglitazone. HbA1c range of 1.00 to 1.60% and FPG 39.1 to 65.3 mg/dl difference from placebo.
* FPG decrease early in the second week.
* Maximum FPG decrease was after 10-14 weeks and continued to the end of therapy.
* There was significant decrease in mean percent triglycerides, increase in HDL cholesterol, and small changes in total cholesterol and LDL for patients receiving 15, 30, or 45 mg Pioglitazone.
* Patients being treated for the first time had greater improvements in HbA1c and FPG. Placebo difference was 2.55% and 79.9mg/dl for those receiving 45-mg compared with those who have been treated previously treated.
* Adverse effects for Pioglitazone and the placebo were the same.
* There was no drug-induced hepatotoxicity or elevations of alanine aminotransferase levels.
Descriptive Discussion
Diabetes is a lifetime and lifestyle disease that causes an increase in an individual's blood sugar level. Diabetes is of two main types that are type 1 and 2 diabetes. Type 2 occurs when the body is producing inadequate insulin for proper functioning or the body cells are unresponsive to insulin (insulin resistance) (Unger, 2012). Diabetes has no cure but treatment and management involves controlling the diabetic symptoms to prevent...